Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

130 Stories from Volunteers, Donors & Supporters

1

Professional with expertise in this field

Rating: 4

Prior to my own introduction with these powerful sacraments, I was unconvinced of there ability to provide structured meaningful therapy for those in need regarding: PTSD, alcoholism, abuse, ect.
But after personally allowing them into my psyche, It has revealed a profound world of endless possibilities for those eager to move in the direction of overcoming. It is ingrained in our being and intertwined in our bio-logy. It increases sensitivity to all of the senses and the ability to get the the bottom of the issue in the right environment (set and setting) far sooner than traditional therepy. It seams immature and childish to regard medicines of this stature as a criminal offence, for something that has the power to change habit and thought.

Professional with expertise in this field

Rating: 5

There doesn't exist a valid excuse for supressing scientific research with psychedelics. Like is said, psychedelics are for psychiatry and neuroscience the same as microscope is for microbiologist. Science is for seeking facts and truth, and it shouldn't be influenced by politics. MAPS is out there to change that and with decades of hard work, they are finally seeing the results. MAPS's work may result in dramatic changes in the medical fields mentioned.

Professional with expertise in this field

Rating: 5

As a physician treating people with opioid addictions, a chronic, relapsing disease where the available treatments have an 85% failure rate, I see the potential to help turn lives around with the use of psychedelics.

Under controlled conditions, in an open, non-judgemental setting where trust is established, it is possible for people who habitually use drugs to obliterate feelings to have the opportunity to experience awareness, trust and joy. No amount of motivational interviewing will allow people to experience what they do not know exists.

MAPS has been very instrumental in raising awareness about these issues and bringing together some of the best and brightest minds in neurology and psychiatry. A respect for the ancient cultures that gave birth to these substances seems to be integrated into their philosophy.

6 LeoŇ°

Professional with expertise in this field

Rating: 5

MAPS has been diclosing the tabu of psychoactive substance adaptive consumption. They have been facing immense legal, political and financal challanges and proved themselve to be patient, tireless and competent. After many years of their activiy we have here several rigorous psychedelic studies done and other precise research of this potent ancient psychotechnologies is coming. Im grateful I could pick up the thread of their work and proceed with promising research which could benefit human health and human-ecosystem relationship and by so it could change the way society understand itself, human nature and nature in general.

7

Professional with expertise in this field

Rating: 4

MAPS has been a courageous spearhead in the struggle to end the prohibition of therapeutically valuable psychedelics. I congratulate Rick Doblin and his staff for undertaking this important work.

Review from Guidestar

11

Professional with expertise in this field

Rating: 5

As a MAPS supporter for many years, I can say, without reservation, that the work Rick Doblin and his staff have done to promote important clinical research has been superlative. I believe MAPS along with The Heffter Society have the potential to manifest new treatment paradigms for many sufferers of mental illness. I believe these have potential for healing psychic wounds which may otherwise not respond to conventional allopathic modalities. Phillip Grob. M.D.

Review from Guidestar

4

Professional with expertise in this field

Rating: 5

As a member of the clinical research community, I was asked to review MAPS conduct of clinical trials and provide guidance. I was incredibly impressed by the clear mission to bring the high standard of clinical research and ICH guidelines to all MAPS research, to ensure data generated would be held with same level of integrity and respect as non-psychadelic (and generally accepted) research methods.

4

Professional with expertise in this field

Rating: 5

I participated a conference titled Psychedelic Sciences in the 21st Century that was sponsored and organized by MAPS. It was an amazingly well-organized and highly informative conference that attracted participants from all over the world. A deeply inspiring and transformative experience for me.

6

Professional with expertise in this field

Rating: 5

MAPS is a refreshing island of curiosity in a sea of prejudice. The prejudice is obvious, surrounding us from the legions of "Just say No" to the pharmacological sloppiness that classes psychedelics with entirely different realms of compounds like the opioids. Objectively, that's just plain ignorant and would not be worth commenting on except that it confuses so many and leads to bad laws. MAPS is sponsoring the leading push toward new scientific information about useful drugs that are trapped behind this societal prejudice. For instance, they sponsored the first FDA-approved study of the effectiveness of MDMA ("Ecstasy") as an adjunct to psychotherapy for intractable cases of Post Traumatic Stress Syndrome. The results, not yet published, are spectacular! Follow-up studies are now planned or underway in Spain, Israel, and Switzerland. Several other psychedelic compounds are to be studied in similarly rigorous ways in US government approved protocols in the near future. None of this vital and fresh information would be possible without the outstanding effort of MAPS. Push back the darkness. The Dark Ages of these useful compounds are nearly over!

6

Professional with expertise in this field

Rating: 5

This may be the only organization that has effectively promoted and executed the research of psychedelic substances for therapeutic benefit in humans. As research in the field of neuroscience progresses, it is being realized that creating therapeutics for the exceedingly complex conditions plaguing the brain is exceptionally difficult. Thus, every available resource that provides either direct therapeutic benefit or opens a new path of discovery should be utilized to its full potential, and the efforts of MAPS is making this possible.